Actinium Pharmaceuticals moves forward with its Phase 1 trial for ATNM-400, a novel non-PSMA targeted alpha therapy designed to treat metastatic castration-resistant prostate cancer.
Actinium Pharmaceuticals is advancing ATNM-400 into further clinical development following positive Phase 1 theranostic trial results. The data confirms the drug's potential as a non-PSMA targeted alpha therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), validating the company's proprietary platform.
ATNM-400 is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
It is a non-PSMA targeted alpha therapy.
Actinium Pharmaceuticals reports positive Phase 1 clinical data for its ATNM-400 theranostic candidate. The trial evaluates the safety and dosimetry of the Zirconium-89-labeled therapy in patients with metastatic castration-resistant prostate cancer.
The trial focuses on assessing the safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400 in patients with mCRPC.